News
Sangamo to Highlight Genomic Medicine Pipeline, Technology Platforms, and Manufacturing Capabilities in December 17 R&D Day
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the Company plans to host an R&D Day on December 17, 2019 at 8am Eastern Time in New York City. Sangamo
Navidea Biopharmaceuticals to Present at the 12th Annual LD Micro Main Event
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
MagForce: Neues Therapiezentrum in Ostdeutschland
Eine der interessantesten Stories unter den Smallcaps in Deutschland liefert schon seit Jahren die Berliner MagForce (WKN: A0HGQF). Dies sah schon vor einiger Zeit auch der bekannte Venture
Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and
Savara Announces the Appointment of Dr. An van Es-Johansson to Board of Directors
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the appointment of Dr. An van Es-Johansson, M.D. to its Board of Directors, effective immediately. Dr. van Es-Johansson
Aurinia to Present Preclinical Voclosporin Data at 2020 Keystone Symposia Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and
Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Singapore for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that its licensing partner Specialised Therapeutics Asia (STA) has received marketing approval of NERLYNX®
1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on
Navidea Biopharmaceuticals Wins Summary Judgment in Ohio
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Biofrontera: Aktie nach Insider-Trades mit Auftrieb
Vorstände zählen wieder zu den Käufern in der Biofrontera-Aktie (WKN: 604611).
CEO Prof. Dr. Hermann Lübbert kaufte heute für knapp 50.000 Euro zu einem durchschnittlichen Kurs von 4,92 Euro. Zu
CORRECTING and REPLACING Puma Biotechnology Amends License Agreement with Pierre Fabre to Include Additional Countries
Epigenomics: Steht der Durchbruch endlich bevor?
Exakt +99% waren im November für flinke Anleger in Epigenomics-Aktien (WKN: A11QW5) von 0,83 auf 1,65 Euro am Freitag drin. Wie es weitergeht, erfährst du nur einen Klick weiter.
Das
ChemoCentryx: Nach +300% - wie geht es jetzt weiter?
Kürzlich explodierte die Aktie des US-amerikanischen Biotechunternehmens ChemoCentryx (WKN: A0NBM2) bekanntlich an einem einzigen Handelstag um mehr als +300% (wir berichteten). Grund hierfür waren
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that on November 26, 2019, the independent members of the Company's Board of Directors granted Badrul Chowdhury, M.D
IMV to Participate at Two Upcoming Investor Conferences
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that the IMV’s executive
Savara’s COO and CMO to Present at the Evercore ISI 2nd Annual HealthCONx Conference
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, will be presenting at the Evercore ISI HealthCONx conference on Wednesday, December 4, 2019 at 2:20 PM ET / 11:20 AM PT at the Four
Sangamo Therapeutics Appoints James R. Meyers to Its Board of Directors
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of James R. Meyers, an accomplished pharmaceutical executive with three decades of commercial
ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting
ArQule, Inc. (Nasdaq: ARQL) today announced that final clinical data from the company-sponsored phase 1 study of ARQ 531 will be presented on December 9, 2019 at the 61st American Society of
Cellectis Wins Patent Challenge in Europe for a Method Using CRISPR-Cas9 for Gene Editing in T-Cells
Regulatory News:
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today
Paion: Marktzulassung von Remimazolam ist auf den Weg gebracht
Wie das kleine deutsche Specialty-Pharma-Unternehmen Paion (WKN: A0B65S) heute vermeldete, hat man nun endlich den Marktzulassungsantrag für Remimazolam in der Kurzsedierung bei der Europäischen
Prothena: NBC-Bonusaktie marschiert +60% in 5 Wochen
Am 29. August stellten wir NBC-Mitgliedern die irische Prothena (WKN: A1KAVV) als Bonusaktie vor. Zu diesem Zeitpunkt hatte die Value-Perle unsere gewünschte Kaufzone bis 7,50 USD bereits
Sangamo Announces UK Authorization of a Phase 1/2 Clinical Trial Evaluating the CAR-Treg Cell Therapy TX200 for Kidney Transplantation
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the United Kingdom’s (UK) Medicines Healthcare Products Regulatory Agency (MHRA) has granted
Biofrontera: Aktie crasht nach heftiger Gewinnwarnung
Die Wachstumsstory bekommt Risse: Biofrontera (WKN: 604611) legt heute seinen 9-Monatsbericht zu den bekannten Eckzahlen vor, die im Oktober wenige Anleger überzeugten (wir berichteten).
In den
Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21 at
Savara Appoints Badrul Chowdhury, M.D., Ph.D as Chief Medical Officer
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the appointment of Badrul Chowdhury, M.D., Ph.D., to the newly created position of Chief Medical Officer (CMO), effective